Current guidelines for treatment of heart failure: 2006 Update

Pharmacotherapy

Volumn 27, Issue 4 PART 2, 2007, Pages

  Uddin, Nabil ^a   Patterson, J Herbert ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aldosterone antagonists; Angiotensin II receptor blockers; ARBs; Heart failure; Treatment guidelines; blockers

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDRALAZINE; ISOSORBIDE DINITRATE; SPIRONOLACTONE; VALSARTAN;

ANGIONEUROTIC EDEMA; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; HYPOTENSION; LOW DRUG DOSE; MEDICAL INFORMATION; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PHARMACIST ATTITUDE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT INDICATION;

EID: 34047120200     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4part2.12S     Document Type: Conference Paper

References (20)

1. Heart Failure Society of America (HFSA). HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Card Fail 1999;5:357-82.
2. American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
3. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40.
4. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;18:736-53.
5. American College of Cardiology/American Heart Association. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Available from http://www.acc.org/clinical/guidelines/failure/update/index.pdf. Accessed August 26, 2005.
6. Adams KF, Lindenfeld J, Arnold JMO, et al. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006;12:10-38.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
9. Pfeffer MA, Braunwald E, Moye LA, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
10. Pfeffer MA, Swedberg K, Granger CB, et al, for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003;362:759-66.
11. Young JB, Dunlap ME, Pfeffer MA, et al, for the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-26.
12. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
13. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
14. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-added trial. Lancet 2003;362:767-71.
15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study (RALES). N Engl J Med 1999;341:709-17.
16. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
17. Packer M, Coats AJ, Fowler MB, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
18. The Cardiac Insufficiency Bisoprolol Study II Group. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
19. The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353:2001-7.
20. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, for the IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-41.